210 related articles for article (PubMed ID: 23468307)
1. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Cortes JE; Nicolini FE; Wetzler M; Lipton JH; Akard L; Craig A; Nanda N; Benichou AC; Leonoudakis J; Khoury HJ; Hochhaus A; Baccarani M; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):584-91. PubMed ID: 23787123
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Cortes J; Lipton JH; Rea D; Digumarti R; Chuah C; Nanda N; Benichou AC; Craig AR; Michallet M; Nicolini FE; Kantarjian H;
Blood; 2012 Sep; 120(13):2573-80. PubMed ID: 22896000
[TBL] [Abstract][Full Text] [Related]
4. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cortes JE; Kantarjian HM; Rea D; Wetzler M; Lipton JH; Akard L; Khoury HJ; Michallet M; Guerci-Bresler A; Chuah C; Hellmann A; Digumarti R; Parikh PM; Legros L; Warzocha K; Baccarani M; Li E; Munteanu M; Nicolini FE
Cancer; 2015 May; 121(10):1637-44. PubMed ID: 25586015
[TBL] [Abstract][Full Text] [Related]
5. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C
Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
[TBL] [Abstract][Full Text] [Related]
6. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
[TBL] [Abstract][Full Text] [Related]
7. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
Alvandi F; Kwitkowski VE; Ko CW; Rothmann MD; Ricci S; Saber H; Ghosh D; Brown J; Pfeiler E; Chikhale E; Grillo J; Bullock J; Kane R; Kaminskas E; Farrell AT; Pazdur R
Oncologist; 2014 Jan; 19(1):94-9. PubMed ID: 24309980
[TBL] [Abstract][Full Text] [Related]
8. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Akard L; Kantarjian HM; Nicolini FE; Wetzler M; Lipton JH; Baccarani M; Jean Khoury H; Kurtin S; Li E; Munteanu M; Cortes J
Leuk Lymphoma; 2016; 57(3):654-65. PubMed ID: 26436949
[TBL] [Abstract][Full Text] [Related]
9. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
10. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Nemunaitis J; Mita A; Stephenson J; Mita MM; Sarantopoulos J; Padmanabhan-Iyer S; Nanda N; Gleich L; Benichou AC; Craig A
Cancer Chemother Pharmacol; 2013 Jan; 71(1):35-41. PubMed ID: 23053254
[TBL] [Abstract][Full Text] [Related]
12. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Nicolini FE; Khoury HJ; Akard L; Rea D; Kantarjian H; Baccarani M; Leonoudakis J; Craig A; Benichou AC; Cortes J
Haematologica; 2013 Jul; 98(7):e78-9. PubMed ID: 23753022
[No Abstract] [Full Text] [Related]
13. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Kim SH; Menon H; Jootar S; Saikia T; Kwak JY; Sohn SK; Park JS; Jeong SH; Kim HJ; Kim YK; Oh SJ; Kim H; Zang DY; Chung JS; Shin HJ; Do YR; Kim JA; Kim DY; Choi CW; Park S; Park HL; Lee GY; Cho DJ; Shin JS; Kim DW
Haematologica; 2014 Jul; 99(7):1191-6. PubMed ID: 24705186
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
[TBL] [Abstract][Full Text] [Related]
16. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
Nicolini FE; Chomel JC; Roy L; Legros L; Chabane K; Ducastelle S; Nicolas-Virelizier E; Michallet M; Tigaud I; Magaud JP; Turhan A; Guilhot F; Hayette S
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):394-9. PubMed ID: 21030353
[TBL] [Abstract][Full Text] [Related]
17. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Damlaj M; Lipton JH; Assouline SE
Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
[TBL] [Abstract][Full Text] [Related]
18. Omacetaxine mepesuccinate for the treatment of leukemia.
Kim TD; Frick M; le Coutre P
Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
[TBL] [Abstract][Full Text] [Related]
19. Omacetaxine as an anticancer therapeutic: what is old is new again.
Wetzler M; Segal D
Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
[TBL] [Abstract][Full Text] [Related]
20. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
Klag T; Härtel N; Erben P; Schwaab J; Schnetzke U; Schenk T; Hochhaus A; La Rosée P
Leukemia; 2012 Jun; 26(6):1321-8. PubMed ID: 22289991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
